Skip to main content
Erschienen in: BMC Infectious Diseases 1/2024

Open Access 01.12.2024 | Case Report

Vagococcus fluvialis isolation from the urine of a bladder cancer patient: a case report

verfasst von: Qian Chen, Siwen Tan, Sheng Long, Kaixuan Wang, Qi Liu

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2024

Abstract

Vagococcus fluvialis infection is rare in humans, and there is limited research on the clinical manifestations and antimicrobial susceptibility testing of Vagococcus fluvialis infection. Here, We isolated Vagococcus fluvialis from the urine samples of bladder cancer patients at Hunan Provincial People’s Hospital, and it is the first reported case of Vagococcus fluvialis isolated from the urine. The fully automated microbial identification system and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) identified the bacterium as Vagococcus fluvialis with a confidence level of 99.9%. The VITEK-2Compact fully automated microbial susceptibility analysis system indicated that it was most sensitive to tigecycline, vancomycin, quinupristin/dalfopristin, linezolid, and showed moderate sensitivity to erythromycin, levofloxacin, ciprofloxacin, ampicillin/sulbactam, and tetracycline. Additionally, it exhibited synergy when combined with high-level gentamicin and vancomycin, showing sensitivity. However, it displayed poor activity against penicillin and furanth. According to our knowledge, this is the first study to isolate and identify Vagococcus fluvialis from the urine of bladder cancer patients and the systematically reviewed other reported Vagococcus infections on human, which provide an experimental basis for guiding the rational use of drugs in the clinical treatment and diagnose of Vagococcus fluvialis infection and related pathogenic mechanism research. Meanwhile, we have systematically reviewed other reported.
Hinweise
Qian Chen MSc and Siwen Tan MSc contributed equally to this work and are joint first authors.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Vagococcus fluvialis is a species in the genus Vagococcus, which is a particular type of Gram-stain positive bacterium that is spherical and similar to lactococci. It can react with anti-sera against lactococci [1]. It was first reported by Collins in 1989 [2]. To date, this bacterium has been isolated from human clinical specimens in several locations [315], including blood, ascites, gallbladder fluid, wound puncture fluid, and root canals. Reports on the pathogenicity of Vagococcus fluvialis are mostly derived from marine animals such as otters, seals, bass, salmon [1619], and rainbow trout, as well as infections in domestic animals such as pigs and cows [20]. This indicates that Vagococcus fluvialis can infect a variety of animals and can also serve as a source of infection in humans. Vagococcus fluvialis isolated from urine samples is rarer, and there are no relevant reported cases in China and abroad. There are different symptoms and physical findings depending on the different areas of the body that are affected.
Vagococcus fluvialis infection is not common in humans, and there is limited research on the clinical manifestations and antimicrobial susceptibility testing of Vagococcus fluvialis infection. Here, We isolated Vagococcus fluvialis isolated from the urine samples of bladder cancer patients at Hunan Provincial People’s Hospital. Through initial verification using colony morphology observation on blood agar plates, Gram staining microscopic analysis, and biochemical experiments with an automatic microbiological detection instrument, this pathogenic bacterium is likely to belong to the rare genus of Vagococcus fluvialis. To ensure accurate identification, in conjunction with relevant literature reports, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) was employed, proving advantageous in identifying rare bacterial species. This study further confirmed the identification of the pathogenic bacterium as riverine roaming cocci through MALDI-TOF MS technology. Meanwhile, we have systematically reviewed other reported Vagococcus infections. It lays an experimental foundation for guiding clinically rational drug use for infections caused by Vagococcus fluvialis and exploring related pathogenic mechanisms.

Materials and methods

Patients and samples

A 60-year-old man presented at Hunan Provincial People’s Hospital with a small amount of blood in his urine, accompanied by urinary frequency, urgency, and pain for over a year. He also had a low-grade fever and blood in his urine constantly for the past 4 days. He did not experience chills, chest tightness, shortness of breath, or difficulty breathing. His mental state, diet, sleep, and bowel movements were normal. Laboratory tests showed that he had a total of 1573.7 red blood cells per microliter, 199.2 white blood cells per microliter, 655.2 bacteria per microliter, a 3 + occult blood in the urine, a 1 + urinary leukocyte esterase, and a 1 + urinary protein. The results suggest that the patient may have a urinary tract infection. Abdominal color Doppler ultrasound showed a solid mass lesion in the anterior and left walls of the bladder. A CTU of the urinary system suggested a bladder mass, with a possibility of malignant tumor originating from the urachus, involving the serosal layer.

Urinary pathogen cultivation and identification

Isolation and cultivation

Urine specimens were collected and inoculated onto Columbia blood agar plates and MacConkey agar plates with alpha-lytic protease inhibitors. The plates were then incubated at 35 °C with 5% CO2 in a incubator-CO2 for 24–48 h, and the colony morphology was observed.

Microscopic examination

Picking a single colony from a blood agar plate of Colombia, preparation of a slide, performing Gram-stain, and microscopic examination using an oil immersion lens.

Strain identification

Picking a pure culture of the test bacterium from a blood agar plate of Colombia, preparing a bacterial suspension of 0.5 McFarland units, based on Gram-stain results, selecting the Gram-stain positive bacteria identification card (GP card) and the Gram-stain positive bacteria susceptibility card (GP67 card) from the VITEK-2 Compact fully automated microbial identification and susceptibility analysis system for testing. The test results are determined using the AES advanced analysis system. Additionally, the test bacterium is streaked onto the target plate of the VITEK MS fully automated rapid microbial mass spectrometry detection system, and 1.0µL CHCA matrix solution is added. After the matrix solution is dried, the sample is analyzed using the machine. Peak comparison and integration calculations are performed using the VITEK MSIVD library, and the identification results are analyzed using the advanced spectrum classifier (ASC) method for high-level mass spectrometry analysis.

Drug sensitivity experiment

Select pure cultures of the test bacteria from Colombia blood agar plates. Prepare a bacterial suspension with a concentration of 0.5 McFarland units. Based on the Gram-stain results, choose the Gram-stain positive bacterial drug sensitivity card, GP67 card, and load it into the VITEK-2 Compact fully automated microbial identification and drug sensitivity analysis system for testing.

Results

Cultivation results

After 24 h of cultivation, the tested bacteria grew into small, pointed, grayish-white, smooth, and raised colonies. There was slight α-hemolysis. After pure cultivation, the colony morphology was more pronounced after 48 h, showing α-hemolysis. The hemolytic zone gradually increased, as shown in Fig. 1.

Gram-stain microscopic examination results

Gram-stain showed positive cocci, relatively small in size, arranged in pairs or chains, as shown in Fig. 2.

Mass spectrometry identification

Mass spectrometry analysis was performed using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) technology to obtain the mass spectrum. Further identification was conducted using the VITEK MS fully automated rapid microbial mass spectrometry detection system. The bacteria was identified as Vagococcus fluvialis (with a confidence level of 99.9%). It exhibits characteristic peak spectra at around 2100 MHz, 4400 MHz, 4800 MHz, 6900 MHz, and 9600 MHz. As shown in Fig. 3.

Drug sensitivity test results

The VITEK-2Compact fully automated microbial susceptibility analysis system indicated that Vagococcus fluvialis is most sensitive to tigecycline, vancomycin, ciprofloxacin/levofloxacin, linezolid, and exhibits intermediate sensitivity to erythromycin, levofloxacin, ciprofloxacin, ampicillin/sulbactam, tetracycline, among other antibiotics. There is a synergistic effect observed when high-level streptomycin is combined with vancomycin, and it shows sensitivity. However, it has poor inhibition effect against penicillin and furantoin.(Table 1).
Table 1
Antimicrobial susceptibility of the Vagococcus flfluvialis strain isolated from patient
 
Antimicrobial
MIC (µg/ml)
1
Penicillin
≥ 64
2
Amoxicillin
16.0
3
High-level synergy of gentamicin
SYN-R
4
High-level synergy of lincomycin
SYN-S
5
Ciprofloxacin
8.0
6
Levofloxacin
8.0
7
Erythromycin
8.0
8
Quinupristin/Dalfopristin
1.0
9
Linezolid
1.0
10
Vancomycin
≤ 0.5
11
Tetracycline
16.0
12
Tigecycline
≤ 0.12
13
Furazolidone
64.0
14
Ceftriaxone
≤ 0.5
Note: MIC means Minimum Inhibitory Concentration; S means susceptible, R means resistance; SYN-S means high-level synergistic test susceptible; SYN-R means high-level synergistic test resistance

Discussion

To date, there have been no reports of culturing Vagococcus fluvialis from human urine specimens, and there are very few reports of human infections caused by Vagococcus fluvialis: In 1997, Teixeira [3] reported the isolation of 4 strains of riverine Vagococcus fluvialis from human clinical specimens, most of which were initially classified as unidentified enterococci. Teixeira confirmed them as Vagococcus fluvialis through the study of phenotypic and genotypic characteristics of the isolates, providing the molecular characteristics of Vagococcus fluvialis and the first evidence of their possible association with human infections. In 2008 [4], Ali Al-Ahmad isolated Vagococcus fluvialis from filled teeth with periapical lesions. In 2019 [9], Jadhav reported a case of Vagococcus fluvialis infective endocarditis. In 2019 [11], Zhou reported the isolation of Vagococcus fluvialis from postoperative infection puncture fluid in the lower segment of the left femur in humans. In 2020 [12], Kucuk reported a case of Vagococcus fluvialis isolated from ascites in a patient with liver cirrhosis. In 2023 [15], Wang first reported the isolation and identification of Vagococcus fluvialis from gallbladder puncture fluid in patients with chronic cholecystitis. Vagococcus fluvialis can also be isolated from various injuries in pigs, cows, cats, tonsils, and the tonsils of horses [20]. It is a Gram-stain positive, catalase-negative cocci. Most of the strains isolated from injury cases were obtained from animals with conditions unrelated to Vagococcus infections. Only a portion of Vagococcus fluvialis strains are motile. Many strains produce positive reactions in the V-P test, alkaline phosphatase, and leucine arylamidase test, or ferment lactose and D-tagatose to produce acid. It has been reported that this bacterium causes severe damage to rainbow trout in fish farming at low water temperatures [21]. Given that Vagococcus fluvialis can cause infections in both humans and animals, and can be isolated from clinical specimens, it is often misidentified or overlooked in clinical laboratories due to diagnostic challenges. Therefore, when isolating suspected Vagococcus fluvialis-like bacteria from various specimens, it is important to differentiate them from relevant bacterial species and perform accurate identification. Meanwhile, we also discovered some advanced materials for precise detection of bacteria, as well as the latest nanomedical approaches for treating bacterial infections, which have propelled new strategies for accurate diagnosis and treatment.
We searched for all cases of human infection with Vagococcus in the PubMed database, Embase database, Google Scholar, China National Knowledge Infrastructure (CNKI), and Wanfang Data. Table 2 shows cases of the previously reported Vagococcus infections in the Literature in humans.
Table 2
Cases of the previously reported Vagococcus infections in the Literature in humans
Ref.
Year of Publication
Age (Years)/Sex
Isolated specimen
Previous diseases/Risk Factors
Duration of Symptoms Before Diagnosis
Diagnosis
Treatmen
Prognosis
Teixeira [3]
1997
N/A
Blood, peritoneal fluid, and wounds
N/A
N/A
Peritonitis, Skin and soft tissue infection
N/A
N/A
Ali Al-Ahmad [4]
2008
N/A
Root canal
N/A
N/A
Periradicular lesions
N/A
N/A
Schinmeister [5]
2009
N/A
Root canal
N/A
N/A
Periradicular lesions
N/A
N/A
Garci [6]
2016
58
Skin wound
Depressive disorder
N/A
Skin and soft tissue infection
Amoxicillin for 15 days
Complete resolution
Abuzaanona [7]
2016
34
Blood
Intravenous drug abuse
N/A
Infective endocarditis and embolic stroke
Ampicillin and Ceftriaxone for 6 weeks
Complete resolution
Raja [8]
2018
N/A
Blood
N/A
N/A
Infective endocarditis
N/A
N/A
Jadhav [9]
2019
70
Blood from patients with infective endocarditis
Coronary artery bypass graft、Aortic regurgitation
3 days
Infective endocarditis
Vancomycin was treated for 6 weeks after aortic valve replacement
Complete resolution
Shewmaker [10]
2019
N/A
Foot wound
N/A
N/A
Foot infection
N/A
N/A
Zhou [11]
2019
19
Infected femoral wound
Left femoral neck fracture、Fracture surgery
10 months
Postoperative wound infection
Expansion surgery and vancomycin bone cement filling
Partial resolution
Kucuk [12]
2020
55
Ascitic fluid
Liver cirrhosis
N/A
Spontaneous bacterial peritonitis
Antibiotic therapy
N/A
Matsuo [13]
2020
74
Blood from patients with decubitus ulcer infection
Decubitus ulcer
4 days
Bacteremia
Piperacillin/tazobactam and vancomycin for 4 weeks
Partial resolution
Altintas [14]
2020
78
Blood
Recurrent urinary tract infections, hysterectomy, hypertension and a cataract operation
4 days
Skin and soft tissue infection
piperacillin/tazobactam for 12 days
Complete resolution
Wang [15]
2023
66
Gallbladder puncture solution
Gastric lymphoma、Post-gastrectomy
N/A
Gallstones with chronic cholecystitis
Cholecystectomy and ceftazidime for a week
Complete resolution
Although Vagococcus fluvialis infections are currently extremely rare, these research reports indicate that if timely and appropriate antimicrobial treatment is not given in clinical practice, it can lead to bloodstream infections, and in severe cases, it can be life-threatening. Studies have shown that Vagococcus fluvialis express a large number of proteins related to known Gram-stain positive bacterial pathogenic and virulence factors, among which enolase and phosphoglycerate kinase are highly expressed, providing further directions for the study of the pathogenic mechanisms of Vagococcus fluvialis [1].
Many literature reports indicate that the main pathogens causing urinary tract infections are Escherichia coli, followed by Staphylococcus spp., Pseudomonas aeruginosa, Klebsiella spp., and Proteus spp. However, cases of Vagococcus fluvialis causing infections are extremely rare. In this study, preliminary verification of the pathogenic bacteria belonging to the rare genus of Vagococcus fluvialis was conducted through colony morphology observations after blood agar plate cultivation, Gram-stain microscopic analysis, automated microbiological detection instrument bioassays. To ensure accurate identification of the pathogenic bacteria, in combination with relevant literature reports, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was used, which has significant advantages in identifying rare bacterial species [10, 22]. In this study, MALDI-TOF MS technology was also utilized for identification and the results once again confirmed it to be Vagococcus fluvialis (with a confidence level of 99.9%).
So far, there is no standard method or criteria for drug sensitivity testing of Vagococcus fluvialis. In this study, the drug sensitivity test of enterococci was used as a reference, which suggests the need for more clinical research to standardize drug sensitivity testing for this bacterium. The patient in this case received cephalosporin treatment for infection upon admission, and based on the patient’s condition and the results of various infection indicators such as blood routine, C-reactive protein, cytokines, and procalcitonin, it was considered that the patient’s infection was still manageable. Postoperative re-examination of urine culture showed no bacterial or fungal growth, and other infection indicators were within normal range. The patient improved and was discharged one week after surgery.
One of the principles of using antimicrobial drugs is that they should not be changed or discontinued arbitrarily. Generally, antimicrobial drugs need to be taken for 2–3 days to reach a certain drug concentration in the body before they take effect. Changing drugs at will is not conducive to the effectiveness of the drugs. The use of antimicrobial drugs should pay attention to the correct drug level. However, not all diseases require high-level drugs. As long as the selected drugs are appropriate, even low-level drugs can exert sufficient effects. Excessive use of high-level drugs can lead to bacterial resistance and affect the efficacy of treatment for severe infections. The selection of appropriate antimicrobial drugs should be based on the characteristics and severity of the infection, and the effects and effectiveness of antimicrobial drugs on pathogenic bacteria are closely related to the characteristics and severity of the disease [23, 24]. Therefore, this case has certain clinical value for diagnose and the rational use of antimicrobial drugs in patients with Vagococcus fluvialis infections.

Acknowledgements

None.

Declarations

Competing interests

The authors declare no competing interests.
This study was approved by the Ethics Committee of The First Affiliated Hospital of Hunan Normal University( The Hunan Provincial People’s hospital).The patients signed an informed consent on clinical data for research.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Conflict of interest/Disclosure

The authors have indicated that they have no conflicts of interest regarding the content of this article.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Cao Y, Zhou T, Duan XL. Identification and preliminary exploration of the proteome of Leptospira interrogans during in vitro cultivation[J]. Chin J Zoonoses. 2020;36(11):900–6. Cao Y, Zhou T, Duan XL. Identification and preliminary exploration of the proteome of Leptospira interrogans during in vitro cultivation[J]. Chin J Zoonoses. 2020;36(11):900–6.
7.
Zurück zum Zitat Abuzaanona A, Al Darzi W, Nour KA. Vagococcus fluvialis causing severe infective endocarditis presenting with embolic stroke: a case report. J Clin Exp Cardiol. 2016;7:8. Abuzaanona A, Al Darzi W, Nour KA. Vagococcus fluvialis causing severe infective endocarditis presenting with embolic stroke: a case report. J Clin Exp Cardiol. 2016;7:8.
10.
Zurück zum Zitat Shewmaker PL, Whitney AM, Gulvik CA, Humrighouse BW, Gartin J, Moura H, Barr JR, Moore ERB, Karlsson R, Pinto TCA, Teixeira LM. Vagococcus bubulae sp. nov., isolated from ground beef, and Vagococcus Vulneris sp. nov., isolated from a human foot wound. Int J Syst Evol MicroBiol. 2019;69(8):2268–76. https://doi.org/10.1099/ijsem.0.003459.CrossRefPubMed Shewmaker PL, Whitney AM, Gulvik CA, Humrighouse BW, Gartin J, Moura H, Barr JR, Moore ERB, Karlsson R, Pinto TCA, Teixeira LM. Vagococcus bubulae sp. nov., isolated from ground beef, and Vagococcus Vulneris sp. nov., isolated from a human foot wound. Int J Syst Evol MicroBiol. 2019;69(8):2268–76. https://​doi.​org/​10.​1099/​ijsem.​0.​003459.CrossRefPubMed
11.
Zurück zum Zitat Zhou T, Cao Y, Duan X. First isolation of Staphylococcus schleiferi subsp. from human postoperative infection fluid in the distal femur [J]. Chin J Hosp Infect. 2019;29(18):2825–9. Zhou T, Cao Y, Duan X. First isolation of Staphylococcus schleiferi subsp. from human postoperative infection fluid in the distal femur [J]. Chin J Hosp Infect. 2019;29(18):2825–9.
13.
Zurück zum Zitat Matsuo T, Mori N, Kawai F, Sakurai A, Toyoda M, Mikami Y, Uehara Y, Furukawa K. Vagococcus fluvialis as a causative pathogen of bloodstream and decubitus ulcer infection: case report and systematic review of the literature. J Infect Chemotherapy: Official J Japan Soc Chemother. 2021;27(2):359–63. https://doi.org/10.1016/j.jiac.2020.09.019.CrossRef Matsuo T, Mori N, Kawai F, Sakurai A, Toyoda M, Mikami Y, Uehara Y, Furukawa K. Vagococcus fluvialis as a causative pathogen of bloodstream and decubitus ulcer infection: case report and systematic review of the literature. J Infect Chemotherapy: Official J Japan Soc Chemother. 2021;27(2):359–63. https://​doi.​org/​10.​1016/​j.​jiac.​2020.​09.​019.CrossRef
15.
Zurück zum Zitat Wang XS, Zhu J, Zhang L. Isolation of Staphylococcus schleiferi subspecies from the bile of a patient with chronic cholecystitis: a case report [J]. J Lab Med. 2023;38(02):200–2. Wang XS, Zhu J, Zhang L. Isolation of Staphylococcus schleiferi subspecies from the bile of a patient with chronic cholecystitis: a case report [J]. J Lab Med. 2023;38(02):200–2.
18.
19.
Zurück zum Zitat Fregeneda-Grandes JM, González-Palacios C, Pérez-Sánchez T, Padilla D, Real F, Aller-Gancedo JM. Limited probiotic effect of Enterococcus gallinarum L1, Vagococcus fluvialis L21 and Lactobacillus plantarum CLFP3 to protect Rainbow Trout against Saprolegniosis. Anim (Basel). 2023;13(5):954. https://doi.org/10.3390/ani13050954.CrossRef Fregeneda-Grandes JM, González-Palacios C, Pérez-Sánchez T, Padilla D, Real F, Aller-Gancedo JM. Limited probiotic effect of Enterococcus gallinarum L1, Vagococcus fluvialis L21 and Lactobacillus plantarum CLFP3 to protect Rainbow Trout against Saprolegniosis. Anim (Basel). 2023;13(5):954. https://​doi.​org/​10.​3390/​ani13050954.CrossRef
Metadaten
Titel
Vagococcus fluvialis isolation from the urine of a bladder cancer patient: a case report
verfasst von
Qian Chen
Siwen Tan
Sheng Long
Kaixuan Wang
Qi Liu
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2024
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09082-w

Weitere Artikel der Ausgabe 1/2024

BMC Infectious Diseases 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.